Related Experiment Video

Updated: Jan 13, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.6K

[The Research Progress of PI3K Inhibitors in the Treatment of Lymphoma --Review]

Wen-Jin Qiang1, De-Li Kong1, Xing-Bin Dai2

  • 1The First Clinical College of Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China.

Zhongguo Shi Yan Xue Ye Xue Za Zhi
|January 8, 2026
PubMed

Insights

Phosphatidylinositol-3-kinase (PI3K) inhibitors show promise for personalized lymphoma treatment. Further research into novel drugs and combination therapies is needed to maximize clinical benefits and improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB/Akt)/mammalian target of rapamycin (mTOR) signaling pathway is crucial in lymphoma development.
  • Dysregulation of this pathway is implicated in various hematological malignancies, including lymphoma.

Purpose of the Study:

  • To review and analyze the latest research on PI3K inhibitors for lymphoma treatment over the past five years.
  • To identify current research hotspots and future directions for PI3K inhibitor development in lymphoma therapy.

Main Methods:

  • Comprehensive literature review of PI3K inhibitor research.
  • Analysis of research and development, clinical applications, efficacy, and adverse reactions.
  • Evaluation of recent clinical trial and basic research findings.

Main Results:

  • PI3K inhibitors are a significant research focus, with ongoing studies on their development, application, efficacy, and safety.
  • Positive outcomes in clinical trials and preclinical research highlight the therapeutic potential of PI3K inhibitors for lymphoma.
  • Current research emphasizes improving drug selectivity and safety, alongside exploring combination therapies.

Conclusions:

  • PI3K inhibitors demonstrate considerable potential for the personalized treatment of lymphoma.
  • Optimizing clinical benefits requires exploring novel, more selective, and safer PI3K inhibitors.
  • Combination therapies involving PI3K inhibitors represent a promising strategy for enhancing treatment efficacy in lymphoma.
Keywords:
lymphoma; PI3K inhibitors; phosphatidylinositol-3-kinase/protein kinase B/mammalian target rapamycin signaling pathway; targeted therapy

More Related Videos

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.5K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K